Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Scientific Publications
  • Investors
    Investors Learn More
    • Financial & Filings
      • Financial Reports
      • Annual General Meeting 2020
      • Extraordinary General Meeting 2020
      • General Meeting Archive
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Videos and Webcasts
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contact
  • Careers
Contact
  • EN
  • FR
Search

In The News

September 24, 2020 Pharmaceutical Technology

Q&A with Valneva: UK Government scales up Covid-19 manufacturing

September 14, 2020 S&P Global Market Intelligence

Valneva CEO optimistic after signing €1.4B COVID-19 vaccine deal with UK

September 14, 2020 Fierce Pharma

Valneva signs $1.6B supply, development agreement with U.K. for coronavirus vaccine hopeful

September 11, 2020 The Science Times

VLA15 May be the First Vaccine Against Lyme Disease

August 5, 2020 NY Times

UK agrees joint investment with Valneva to boost vaccine production

July 20, 2020 Precision Vaccinations

French Firm Joins UK Coronavirus Vaccine Initiative

July 20, 2020 Reuters

Valneva eyes EU COVID-19 vaccine deal after agreeing to supply UK

July 20, 2020 fiercepharma.com

Niche vaccine player Valneva, U.K. tie up in coronavirus R&D and manufacturing deal

July 20, 2020 Forbes

Britain Secures 90 Million Doses Of Potential Coronavirus Vaccines From Pfizer, BioNTech & Valneva

June 10, 2020 BioSpace

Past Vaccine Failures May Reduce COVID-19 Vaccination Rates

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2021 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT Reject
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT